Articles Published in 2007 Articles | CenterWatch News Online

Articles Published in 2007

Prev 10 11 12 13 14 15 16 17 18 19 20

CFOs in Demand at CROs

Thursday, June 7, 2007 11:06 AM

On April 30 when PPD announced that Linda Baddour, chief financial and accounting officer, was resigning effective May 31, the contract research organization (CRO) added that Baddour would be providing consulting services to the company for the next six months to assist with the transition of her responsibilities to other members of senior management.

More... »

Recent Industry Personnel News

Wednesday, June 6, 2007 02:39 PM

Inclinix, a patient enrollment CRO based in Wilmington, N.C., has announced a series of personnel changes to the company’s executive management team. Inclinix promoted Robert Bernosky to executive vice president, strategic activities. Bernosky was formerly chief financial officer. That role will be filled by Jeffery Reiniche. Prior to Inclinix, Reiniche served in various roles at Click Commerce, Health Alliance and PriceWaterhouseCoopers. Bill Gwinn, formerly of Thomson MedStat and IMS Health, has joined the company in the newly created role of vice president, product marketing. And Robert Welch has joined the company as director, strategic accounts. Retiring from the Inclinix is senior vice president Bryan McIntyre.

More... »

Bilcare To Create Research Academy in India and Asia

Tuesday, June 5, 2007 06:45 AM

India-based Bilcare Limited, a pharmaceutical packaging and clinical technology firm, together with the Association of Clinical Research Professionals (ACRP), have created the Bilcare Research Academy. The company will open 25 educational centers in India and Asia by 2010, investing $4.8 million. The first centers to open in India and Singapore, followed later by Thailand, Pakistan, Bangladesh, Sri Lanka, Indonesia and China.

More... »

Novartis And Vanda See Positive Results With iloperidone

Monday, June 4, 2007 03:53 PM

Novartis and Vanda Pharmaceuticals reported positive results from a phase III trial of iloperidone for the treatment of akathisia in schizophrenia. This randomized, double-blind, placebo controlled trial enrolled 706 subjects who were placed into one of four treatment groups: iloperidone 12.16 mg/d or 20.24 mg/d, risperidone 6.8 mg/d or placebo for 6 weeks. Changes in akathisia were measured weekly by the Barnes Akathisia Scale (BAS) and the Extrapyramidal Symptom Rating Scale (ESRS) from baseline to the six-week end point.

More... »

InVentiv Health Acquires Addison Whitney

Thursday, May 31, 2007 01:43 PM

CenterWatch has been watching for years the goings on at Somerset, N.J.-based inVentiv Health. The billion-dollar company is on another buying spree and we’ve been interested in what it continues to do in the contract research space. In March 2006, inVentiv bought Synergos, a clinical services provider with expertise in clinical trial management services, including project management and monitoring as well as investigator and patient recruitment. Synergos, which was purchased for $5.75 million in cash and stock plus earn-outs, operates under inVentiv’s clinical division.

More... »

Cost of Compliance Rising for AHCs

Thursday, May 31, 2007 10:36 AM

The Association of Academic Health Centers (AAHC), a non-profit organization supports the nation's academic health centers, has released a paper reporting that its members are allocating higher amounts of funds towards increasingly burdensome clinical trial compliance requirements. The AAHC placed investing in compliance as its top priority and called the requirements essential for ensuring safe and effective trials. However, the AAHC stated the cost of compliance is a national issue facing the entire academic health center (AHC) enterprise. The report said that for a one-year period, some AHCs reported compliance costs increased as much as 70%. The paper is called Investing in Clinical Trial Compliance.

More... »

Recent Industry Personnel News

Tuesday, May 29, 2007 07:00 AM

MDS Pharma Services, a contract research organization (CRO) based in King of Prussia, Pa. has named James Pusey as the company’s vice president and general manager of its global clinical development business. The group manages MDS’ late stage trials. Prior to MDS, Pusey was chief executive officer at the biotech company OrthoLogic. He also served as executive vice president for neurology at Serono and a vice president of marketing at AstraZeneca’s CNS, Pain and Infection group.

More... »